Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Bevacizumab Rechallenge in Advanced Non-squamous NSCLC
NCT02200354Phase 2Terminated
- Sponsor
- Kobe City Medical Center General Hospital
- Start
- Jul 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed and bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Kobe City Medical Center General Hospital. Primary endpoint: Progression-Free Survival at 16 weeks. Started Jul 2014; status: terminated.
02
Drugs
pemetrexedbevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02200354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200354.